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Uricase is the enzyme responsible for the breakdown of uric acid, the key molecule lead-
ing to gout in humans, into allantoin, but it is absent in humans. It has been produced as a
PEGylated pharmaceutical where the purification is performed through three sequential
chromatographic columns. More recently an aqueous two-phase system (ATPS) was reported
that could recover Uricase with high yield and purity. Although the use of ATPS can
decrease cost and time, it also generates a large amount of waste. The ability, therefore, to
recycle key components of ATPS is of interest. Economic modelling is a powerful tool that
allows the bioprocess engineer to compare possible outcomes and find areas where further
research or optimization might be required without recourse to extensive experiments and
time. This research provides an economic analysis using the commercial software BioSolve
of the strategies for Uricase production: chromatographic and ATPS, and includes a third
bioprocess that uses material recycling. The key parameters that affect the process the most
were located via a sensitivity analysis and evaluated with a Monte Carlo analysis. Results
show that ATPS is far less expensive than chromatography, but that there is an area where
the cost of production of both bioprocesses overlap. Furthermore, recycling does not impact
the cost of production. This study serves to provide a framework for the economic analysis
of Uricase production using alternative techniques. VC 2015 The Authors Biotechnology
Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical
Engineers, 32:126–133, 2016
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Introduction
Urate oxidase or uricase, (E.C.1.7.3.3) is an enzyme
responsible for the breakdown of uric acid into allantoin.1 It
is a tetrameric protein and each subunit has a mass of 34
kDa.2 Because this protein is absent in humans and higher
apes due to evolutionary mutations,3–5 uric acid is the end
product of the purine metabolism. This allows the possibil-
ity, intensified by a purine-rich diet, to accumulate uric acid
in the bloodstream. When the concentration of uric acid
exceeds 7 mg/dL (hyperuricemia), it can precipitate and gen-
erate needle-like crystals,6 causing acute pain, inflammation
and possible formation of tophi, leading to the development
of a type arthritis, known as Gout.7
Uricase is an attractive therapy for reducing the uric acid
concentration. Allantoin is a soluble molecule in plasma,
which can be easily eliminated through the kidneys as it is
5–10 times more soluble than uric acid.8 This enzyme has
been developed as a pharmaceutical and is expressed in a
recombinant host and is delivered as a PEGylated form to
improve pharmacokinetics by increasing its size and reduc-
ing immunogenicity.6,9
Uricase has been isolated and cloned from Aspergillus fla-
vus,10 Pseudomonas aeruginosa,11 Candida utilis,12 etc. Pro-
duction consists of expression in E. coli as an intracellular
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soluble protein and purification by sequential chromato-
graphic steps.2,8,13,14 Recently, recovery by aqueous two-
phase systems (ATPS) has been reported to achieve a high
level of recovery and pharmaceutical purity.15 This alterna-
tive eliminates the use of chromatography in the purification
of Uricase. ATPS have been reported to be a less expensive
and time consuming operation compared with chromatogra-
phy, therefore saving resources through process integration
and intensification.16
One of the main disadvantages of using ATPS, at indus-
trial scale, is the high quantity of materials that need to be
disposed of later. Estimates show that the total operation vol-
ume can be 10–20 times larger than the input product vol-
ume used.15,17 With this in mind, research has been
conducted to reduce the quantity of materials required by
recycling the polymers used, especially polyethylene glycol
(PEG).18–21 To accomplish this the basic concept is to use
back-extraction,18 which consists of using two sequential
ATPS steps, the first recovers the protein in the top phase
then on the second ATPS (using the previous top phase as a
base) the protein is forced to migrate to the bottom phase.
The top phase of the second ATPS can now provide the
materials to construct the first ATPS, while the fraction that
now contains the protein (bottom phase of the second ATPS)
can be filtered to remove the ATPS components and perform
a buffer exchange. This could further decrease production
costs and also the level of waste disposal.
When designing or improving a bioprocess, it is important
to consider possible scenarios that occur during real develop-
ment. Using bioprocess modelling it is possible to create vir-
tual bioprocesses, allowing input parameters, obtained
through research, to be varied so as to obtain estimates of
the cost of production per gram (Cost of Goods per gram,
CoG/g). Use of such model-based tools can also help to
decrease the costs of research by saving time and resources,
reducing the number of experiments and focusing efforts
where it is needed.22,23 Furthermore, it is possible to incor-
porate uncertainties that are inherent of any bioprocess.24
This area has gained attention recently with publications
including those to compare the costs of production between
using stainless steel or single-use equipment,24 analysis of
pooling strategies in perfusion cultures,25 evaluation of batch
or continuous cell culture strategies26 and the effect of opti-
mization of selected process parameters.27 Such research
publications provide crucial insights on whether certain strat-
egies are likely to be better than others without the need to
carry out extensive experiments.
A range of software tools have been developed to perform
bioprocess modelling and economical analysis.28,29 These
include BioSolve (Biopharm Services, Chesham, Bucking-
hamshire, UK), SimBioPharma (University College London,
London, UK), SuperPro Designer (Intelligen, Scotch Plains,
NJ), Aspen Batch Plus (Aspen Technology, Cambridge, MA),
etc. BioSolve is an Excel-based software, that takes into
account direct and indirect costs and contains an extensive
library for equipment and materials with costs collected
directly from suppliers. This software allows the user to cre-
ate putative bioprocesses and obtain the cost of production, it
has a large collection of operations, which can be assembled
in many combinations and analyze the impact of each config-
uration. It also allows to manipulate most of the parameters
and obtain results of hypothetical scenarios. The main focus
of BioSolve is to obtain the cost of production, while other
software is more focused on the engineering part.
This work presents an economic analysis of putative bio-
processes based on reported purification strategies for Uri-
case. Business related factors were not considered. The
article describes the comparison between the chromato-
graphic and ATPS purification techniques by creating bio-
process flowsheets that achieve the same levels of
production but which each employ different unit operations.
Which parameters affect most the CoG/g were then deter-
mined via a sensitivity analysis. A Monte Carlo Analysis
was performed on the chromatographic, ATPS and ATPS
incorporating a recycling (back-extraction) step, in each case
to mimic real manufacturing behavior. These studies were
performed so as to analyze the impact of changing the purifi-
cation method and later the addition of an unit operation for
PEG recycling on the overall process economics.
Model Set-Up and Deterministic Analysis
This section details the set-up of the models in BioSolve
used to calculate the CoG/g for the production of Uricase.
The models were based on published articles that describe
purification with chromatography2 and ATPS.15 Separately,
the ATPS model was modified to include a second ATPS
step for the back-extraction (Uricase movement to salt-rich
phase) and recycling of PEG. The back-extraction was based
on the recovery of a different protein that uses similar condi-
tions for the construction of the ATPS for its recovery.18,30
The mechanism of the back-extraction is explained in detail
later in this paper.
The size of the bioprocesses was based on a chromato-
graphic purification2 (the largest production reported for Uri-
case). This used a 25 L E. coli fermentation achieving a titer
of 0.5 g/L. The chromatographic process was modified
slightly by the addition of a centrifuge for biomass recovery,
high pressure homogenization to release the intracellular
material and a second centrifuge for cell debris removal. An
additional unit operation at the end of the process was
added; an Ultrafiltration/Diafiltration (UF/DF) step for con-
centration and buffer exchange. For the ATPS bioprocess,
the three chromatographic columns were changed to a single
ATPS step. The UF/DF was used to remove ATPS compo-
nents while concentrating the sample. The sequences of
operations are shown in Figure 1. Recovery yields were
taken from their respective publications,2,15 for the chro-
matographic process the final yield is 43.2% and for ATPS
process is 66%. The added unit operations (centrifuges and
homogenization) were used according to the default parame-
ters provided by BioSolve.
A relevant comparison can only be made if both processes
achieve similar purity. The ATPS operation is based on the
production from Candida utilis, but analysing both biopro-
cesses in their respective publications,2,15 it is found that
they can achieve a specific activity (enzyme units per mg of
total protein) of 27 U/mg. In terms of proteins, it means that
they have the same purity, but in a real crude extract there
are other contaminants (for example nucleic acids), the
ATPS report doesn’t include information on this, but as the
product will have a pharmaceutical use, additional operations
need to be included in both processes (viral inactivation,
nucleic acids removal, etc.), but as these are polishing opera-
tions they were excluded from this analysis to focus on con-
trasting chromatography and ATPS.
It is important to mention that both bioprocesses achieve 27
U/mg, but the chromatographic process achieves 25.7 U/mg
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in the first two chromatographic columns, the third improves
this to 27 U/mg, the complete chromatographic process was
considered for the analysis as this can achieve a purity of
99% and a 3 sequential array of chromatographic columns is
the most reported form to purify Uricase.
Both bioprocesses were assumed to achieve the same titer,
require identical reactor volumes, operators (Labor) and
Quality Control (QC) tests. Labor was set to be 13% of the
total CoG/g, as it has been reported to be between 10 and
15% for recombinant protein production23 with the exact
wage values set to the average for the United Kingdom.31
QC test were modified from the default in BioSolve, as they
are focused to monoclonal antibodies (Mabs), most of them
were preserved but those specific to Mabs were excluded, in
this case only the measurement of residual protein A was
left out. The costs of equipment and material needed for the
processes were obtained from the library included in the Bio-
Solve software. The only other inputs were the media and
solutions used, particularly for the fermentation, ATPS solu-
tions and chromatographic buffers.
After setting-up the models, the CoG/g for the base sce-
nario were returned as $9,400 and $5,450 for the chro-
matographic and ATPS processes, respectively. The ability
of BioSolve to break down the CoG/g to its components was
used to identify the main contributors. In Figure 2, it can be
seen that the costs for capital, consumables, labor, and others
are lower for the ATPS bioprocess, while materials were
lower for the chromatographic purification. This reflects the
nature of each bioprocess. Chromatography has larger capital
costs because of the need to acquire more equipment than
ATPS process. ATPS recovery needs the input of large quan-
tities of material to construct each system while chromatog-
raphy requires new resins with constant turnover and a
larger level of consumption of consumables. The difference
in consumables usage between the two process options is not
as large as for materials due to the fact that the ATPS bio-
process requires a larger supply of UF/DF filters because of
the nature of the operation which requires significant vol-
umes to be filtered in order to remove the PEG from solu-
tion, each filter has a certain limit of volume to process and
by filtering more the lifetime becomes shorter.
Sensitivity Analysis
The values of the parameters that determine the CoG/g in
a bioprocess are not constant. Parameters that affect the
CoG/g the most in a bioprocess can be fermentation titer,
desired final production (target output), downstream process-
ing yield (DSP yield), material costs and labour
wages.24,25,32 To capture the essence of this, a sensitivity
analysis was performed in which a best and worst case sce-
nario were created for every parameter. Target output was
held constant so as to provide a common basis for the com-
parison between the process options. The sensitivity analysis
was carried out by changing systematically each parameter
individually. Table 1 shows the scenarios used in this sensi-
tivity analysis.
The titer range was developed by obtaining the mean (61
standard deviation) from the calculated titer needed to yield
the level of production cited for a process based upon chro-
matographic purification.2 According to the literature,24,25,32
DSP yield was modified by6 10% and material costs by
Figure 1. Bioprocesses designed for the production of uricase. Conventional chromatographic process—process using ATPS.
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625%, for those materials that affect the most; fermentation
media (23 YT medium), ATPS materials (PEG2000, ammo-
nium sulfate, sodium chloride) and UF/DF filters. Labor
wages were adjusted to the prevailing pay rate in two coun-
tries selected to have higher and lower salaries compared to
the United Kingdom, respectively. The United States (US)
was chosen as the former because of the large concentration
of biotechnology companies and suppliers and Mexico for
the latter as it offers comparatively lower wages.
Figure 3 shows the results of the sensitivity analysis. In
both bioprocesses, the two key parameters were fermentation
titer and DSP yield. In the case of chromatographic purifica-
tion, DSP yield was the most important parameter. A slight
change had a larger impact because of the extended process
sequence, while in the ATPS case, with fewer unit opera-
tions, DSP yield had less impact and the fermentation titer
dictates the final production and therefore had the bigger
impact on the CoG/g. The third and fourth parameters
ranked in importance were labour and material costs. In the
ATPS process, materials were a bigger concern as they are
required in large quantities to construct the system, but there
is also a need for more UF/DF filters to remove the PEG
from the solution. On the other hand, chromatographic resins
can be reused and in bind-and-elute processes samples can
be concentrated whereas in ATPS they are diluted. This fea-
ture means that materials costs have a lower impact on the
chromatographic-based purification process.
At this point in the analysis, the impact of changes in indi-
vidual parameters had been analyzed. Moreover in a real
process, parameter changes occur simultaneously and it is
important to analyze them in a synergistic fashion as
described next.
Monte Carlo Analysis
A Monte Carlo analysis was performed to understand how
CoG/g behaves when key parameters are allowed to vary
simultaneously. The top two parameters from the sensitivity
analysis were examined (Fermentation titer and DSP yield).
To perform this analysis a program was written in Visual
Basic to generate random values for both parameters as
inputs to BioSolve, which in turn computed the correspond-
ing CoG/g values. A probabilistic function was used to gen-
erate random values for the parameters. A triangular
distribution with the same limits (most-common, maximum
and minimum) as in the sensitivity analysis was assumed as
this is a frequently used distribution in the bioprocesses liter-
ature.26,33 A moving average (MA) was calculated after each
run with stable outcomes achieved after 300 simulations.
This was taken as a standard for the Monte Carlo analysis.
Figures 4a–c shows the results for the simulation runs.
Figure 2. Breakdown per cost categories of the CoG/g obtained
in the deterministic analysis. (a) Shows the break-
down according to percentages, while (b) shows the
breakdown in absolute terms. Chromatographic-
based process; ATPS.
Table 1. Scenarios Used for the Sensitivity Analysis
Scenarios
Variable Best Base Worst
Titer (g/L) 0.577 0.484 0.392
DSP Yield (6%) 110 0 210
Material Cost (6%) 225 0 125
Labor (Location) Mexico UK USA
Production operator ($) 41,872 32,935 37,689
Production supervisor ($) 52,337 38,490 37,689
Quality assurance ($) 70,149 56,176 35,995
QC ($) 39,101 31,400 35,995
Figure 3. Tornado plot for the results of the sensitivity analy-
sis. (a) Chromatographic-based process (vertical axis
cross at base scenario: $9,396.97) and (b) ATPS-
based process (base scenario: $5452.00).
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Figure 4a shows the complete results in a tridimensional
environment. Simplified views are provided in Figures 4b,c.
Having either a higher titer or a DSP yield results in a lower
CoG/g, while a decrease in titer and DSP yield produces a
higher CoG/g. If high titer and high DSP yield are combined
the lowest possible CoG/g is achieved. Analysing Figures
4b,c, it can be seen that as the CoG/g decreases it also tends
to stabilize. It can be inferred that there is a condition for
titer and DSP yield where they are no longer the main con-
tributors to the change of the CoG/g. This means that there
is a critical point where the CoG/g is dependent on a
product-oriented parameter rather than on a process-oriented
parameter. It is reported elsewhere,27 when titer (a process
parameter) was optimized the main parameter became target-
output (a product-parameter). A zone exists where both chro-
matographic and ATPS purification based processes overlap
and have a similar CoG/g. This occurs when the
chromatographic-based bioprocess is operated at best condi-
tions (the highest titer and DSP yield) and ATPS recovery
operated at worst conditions.
An additional bioprocess based on recycling the ATPS
was included. In this, a second ATPS system is added where
Uricase migrates to the bottom phase leaving a PEG-rich top
phase that can be reused as material for the first ATPS.
According to the literature,17,18 this can be achieved when
the percentage of salt (in this case ammonium sulfate) is
greater than that of the polymer and the volume of the bot-
tom phase is greater than the top phase volume. Figure 5
shows how the components of the systems move between
both elements of the ATPS and the conditions necessary for
each extraction. Recycling with back-extraction allows reuse
of 60% of the PEG, 20% of (NH4)2SO4 and 20% of NaCl.
18
This mode of operation reduces the cost of the first ATPS by
reducing the total inventory of materials needed. The process
based upon recycling and back-extraction was compared
with the traditional ATPS and the results are shown in
Figure 6. It can be seen there is not a clear difference
between the two options. The deterministic result for the
new bioprocess CoG/g is $5430, slightly lower than the sim-
ple ATPS bioprocess. When Monte Carlo analysis was
applied the distribution of costs was almost identical.
Even though the addition of recycling decreases signifi-
cantly the amount of material required for every batch, the
CoG/g does not decrease at the same rate because of the
dominance of the UF/DF operation. In the modified process
there is a significant level of dilution. The second ATPS was
made taking into account the solute composition passed on
Figure 4. Monte Carlo Analysis results examining the impact
of titer and DSP yield on CoG/g for
Chromatographic-based and ATPS without recycle
processes. (a) 3-D representation of both CoG/g dis-
tributions. (b) 2-D representation of distributions
with titer in the x-axis and color variable for DSP
yield, while (c) has the DSP yield on the x-axis and
titer as color variable.
Figure 5. Representation of the back-extraction used in the
third, putative, bioprocess. The first system is con-
structed by the mixing of the sample (coming from
the centrifuge after cell debris removal), PEG and
ammonium sulfate, the bottom phase is discarded.
The second system uses the top-phase from the pre-
vious system as a source of material but still has a
fresh input of (NH4)2SO4, the top-phase is now
returned as material for construction of the first sys-
tem. The bottom-phase enriched in Uricase is used
for further purification.
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from the previous top phase. The volume input to the second
ATPS is only a fraction of the total volume. The output col-
lected for further purification was 56% of the second system,
which equates to a final dilution of 10 times the initial sam-
ple input and hence a large volume increase but a lower
PEG concentration compared to the original top phase from
the ATPS bioprocess without recycle. UF/DF is still needed
to remove the salts and residual PEG. This causes an
increase in the cost of the UF/DF operation, because more
volume is being filtered. Although recycling decreases the
costs of making up the ATPS this saving is not sufficient to
decrease the final overall CoG/g appreciably.
Linear models were generated for each of the 3 compara-
tive processes and the results are presented on Table 2. All
of the parameters and the intercepts are significant at a value
of a5 0.01. The values for the coefficients are consistent
with the graph in Figure 4a. When titer and DSP yield
change, they impact most the CoG/g for the chromatography
bioprocess, while the CoG/g changes more slowly for the
ATPS bioprocesses (both with and without recycle). Linear
models also showed negligible CoG/g differences between
ATPS with and without recycle. The DSP yield coefficient
was slightly greater in recycling, but this might be an arte-
fact of the addition of an unit operation. The same situation
was presented during the sensitivity analysis, where the
chromatographic-based bioprocess was seen to be more sen-
sitive to changes in DSP yield due to the larger number of
process steps compared withATPS.
Analysis of the linear models revealed, as mentioned
before, an area of overlapping CoG/g as follows:
chromatographic-based process requires to operate in the top
23% of all possible values obtained under the probabilistic
function, while the ATPS needs to operate in the bottom
52%. These results are not promising as the chromatographic
purification has been extensively optimized already. For the
ATPS option, there is still space for optimization, which
offers scope to reduce the overlapping area by optimizing
the ATPS recovery and therefore decreasing the CoG/g
through the use of this unit operation in preference to chro-
matography. The result is indicative of the potential for
ATPS to be used in commercial bioprocesses.
There are other potential strategies to reduce the amount
of waste generated by the ATPS processes and to recycle
material. When using back-extraction, to achieve a signifi-
cant decrease in the CoG/g, it is important to decrease the
volume to be filtered and hence reduce the dominance of the
UF/DF. In the back-extraction employed in this study, the
bottom phase volume was larger than the top phase. It is
however possible to tailor a ATPS for this particular protein
such that the relative volume< 1 (ratio of volumes of the
top and bottom phases) whilst still maintaining a high level
of recovery and purity. This should also ensure that the vol-
ume to be processed by the UF/DF remains comparable to
that of the simple ATPS process studied here. One potential
alternative strategy is to saturate the phase to which the pro-
tein of interest migrates. This requires the system to be set-
up as before but then to remove the phase which is rich in
contaminants; for this system the bottom phase. After that
fresh components are added to the preserved top phase to
form a new bottom phase and a new sample added. Uricase
will once more migrate to the top phase, but now as this
phase is already loaded with protein the efficiency of capture
will be reduced. Experimental research can locate the bal-
ance between the number of cycles for saturation and protein
recovery, whilst still achieving a decrease in the CoG/g.
Figure 6. Comparison of the results of Monte Carlo analysis
for ATPS with and without recycle. (a) Impact of
titer and (b) impact of DSP yield.
Table 2. Linear Models Calculated for CoG/g in Terms of Titer and Downstream Processing Yield (P-values 3 10216).
Chromatography ATPS ATPS with Recycle
Coefficient P-value Coefficient P-value Coefficient P-value
Intercept 191,956 <2 11,013 <2 10,917 <2
Titer 219,883 <2 211,374 <2 211,224 <2
DSP Yield 2227 <2 283 <2 283 <2
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Conclusions
This article describes an economic analysis of three possi-
ble routes for the production of Uricase for pharmaceutical
use carried out using a commercial software package. It was
possible to identify the key parameters that affect most the
costs of production for each bioprocess studied: conventional
chromatographic-based purification, simple ATPS use and
ATPS with phase recycle. A series of Monte Carlo simula-
tions were performed to understand how much the distribu-
tion of CoG/g behaves when uncertainty in process
parameter values was considered. It was found that when
titer and DSP increase CoG/g decreases but toward a stable
outcome, suggesting an increase of the level of importance
of product-oriented variables. According to the linear models
fitted to the dataset, an area of overlap exists where the
ATPS and chromatographic-based purification processes
have similar CoG/g.
A third putative bioprocess was incorporated based on
ATPS but which included recycling of materials. This option
decreased the amount of materials needed but the CoG/g did
not decrease significantly due to an increase of the unit oper-
ation costs which reflect the high volumes of material which
have to be processed in such a process option. Methods to
achieve a lower CoG/g for ATPS with recycling are briefly
discussed. Performance is strongly dependent upon the abil-
ity to optimize phase recycling.
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